ClinicalTrials.gg
CompletedNCT05051566Updated May 29, 2026Results posted

A Multiple Dose Study of LY3502970 in Healthy Participants

A Phase 1 interventional study of LY3502970 and Esomeprazole in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to assess how fast LY3502970 gets into the blood stream and how long it takes the body to remove it when administered in multiple oral doses as new formulation compared to that of reference LY3502970 formulation. Information about safety and tolerability will be collected. The study is open to healthy participants. The study is conducted in two parts and it will last up to about 6 months, inclusive of screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation.
  • (BMI) of 18.5 to 35 kilograms per meter squared (kg/m²).

Exclusion criteria

Exclusion Criteria:

  • Have an abnormal blood pressure and/or pulse rate as determined by the investigator -minor deviations acceptable to investigator are allowed
  • Have known liver disease, obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, or have elevations in aminotransferases ( [ALT] and aspartate aminotransferase [AST]) greater than 2X (Upper Limit of Normal)
  • Have an abnormality in the 12-lead at screening that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Are women of
  • Are women who are lactating
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Part A

    * Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received single escalating doses of LY3502970 oral capsule every 6 days, starting with a dose of 2 milligrams (mg), increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19. * Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 reference oral capsule once daily (QD) * Test Phase/Fasted state (Day 25 to Day 36): On Day 25, participants were randomly assigned to receive 16 mg of LY3502970 QD, either as Prototype 1 tablet or Prototype 2 tablet, and continued through Day 30 (Test Phase 1). On Day 31, participants crossover to the other prototype formulation (i.e., those who initially received prototype 1 now receive prototype 2, and vice versa), continuing through Day 36 (Test Phase 2).

    Drug: LY3502970

  • Experimental
    Part B

    * Dose Titration Phase/Fasted state (Day 1 to Day 18): Participants received single escalating doses of LY3502970 oral capsule every 6 days, starting with a dose of 2 mg, increasing to 4 mg, then 8 mg, and reaching a maximum dose of 16 mg by Day 19. * Reference Phase/Fasted state (Day 19 to Day 24): Participants received 16 mg of LY3502970 prototype 2 tablet QD. * Test Phase 1/Fed state (Day 25 to Day 30): During this phase, participants were administered 16 mg of LY3502970 prototype 2 tablet QD. * Test Phase 2/Fasted state (Day 31 to Day 36): During this phase, participants were administered a PPI 40 mg Esomeprazole tablet first, followed by 16 mg of LY3502970 prototype 2 tablet QD. The PPI was administered to elevate gastric pH (potential of hydrogen), and PK (pharmacokinetic) parameters were evaluated under these elevated gastric pH conditions

    Drug: LY3502970 · Drug: Esomeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

    Part A: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)

  2. Part A: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-Dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

    Part A: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)

  3. Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

    Part A: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)

  4. Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

    Part B: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)

  5. Part B: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

    Part B: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)

  6. Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

    Part B: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.

    Time frame: Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)

07

Results

Posted May 29, 2026

Participant flow

The study was conducted in 2 parts: Part A: This is the initial formulation evaluation phase, where multiple oral doses of LY3502970 formulation prototypes were tested in a group of participants. Part B: This is the secondary evaluation phase in another group of participants, where, depending on the results of Part A, one of the prototypes may be further evaluated with regard to the effects of food, proton pump inhibitors (PPIs), or additional prototype formulations may be explored.

Participant flow — Overall Study
MilestonePart APart B
Started1214
Received at least 1 dose of study drug (safety analyses set)1214
Completed1012
Not completed22
Withdrew: Withdrawal by subject20
Withdrew: Adverse event02

Outcome measures

PrimaryPart A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

Part A: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Part A: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
nanograms per milliliter (ng/mL)Part A (LY3502970)
16 mg reference capsule (Day 24)66.2 ± 77.4
16 mg prototype 1 tablet (Days 30 and 36)111 ± 81.2
16 mg prototype 2 tablet (Days 30 and 36)97.4 ± 58.9
PrimaryPart A: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-Dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

Part A: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Reported as:
Geometric mean · nanogram*hours per milliliter (ng*h/mL)
Part A: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-Dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
nanogram*hours per milliliter (ng*h/mL)Part A (LY3502970)
16 mg reference capsule (Day 24)988 ± 66.9
16 mg prototype 1 tablet (Days 30 and 36)1480 ± 75.2
16 mg prototype 2 tablet (Days 30 and 36)1400 ± 51.2
PrimaryPart A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

Part A: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following: 16 mg reference capsule on Day 24, 16 mg Prototype 1 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2), and 16 mg Prototype 2 tablet administered on Day 30 (last/sixth dose of Test Phase 1) and Day 36 (last/sixth dose of Test Phase 2).

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Reported as:
Median · hours
Part A: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
hoursPart A (LY3502970)
16 mg reference capsule (Day 24)7.02 (4 to 8)
16 mg prototype 1 tablet (Days 30 and 36)8 (4 to 16)
16 mg prototype 2 tablet (Days 30 and 36)8 (4 to 16)
PrimaryPart B: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

Part B: Cmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Reported as:
Geometric mean · ng/mL
Part B: PK: Maximum Observed Concentration (Cmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
ng/mLPart B
16 mg prototype 2 tablet (Fasted) (Day 24)63.4 ± 32.2
16 mg prototype 2 tablet (Fed) (Day 30)56.3 ± 29.6
16 mg Prototype 2 tablet + PPI (Fasted) (Day 36)59.6 ± 51.0
PrimaryPart B: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

Part B: AUC(0-24) of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Reported as:
Geometric mean · ng*h/mL
Part B: PK: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours Post-dose (AUC(0-24)) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
ng*h/mLPart B
16 mg prototype 2 tablet (Fasted) (Day 24)903 ± 25.3
16 mg prototype 2 tablet (Fed) (Day 30)865 ± 24.6
16 mg Prototype 2 tablet + PPI (Fasted) (Day 36)956 ± 40.1
PrimaryPart B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation

Part B: Tmax of LY3502970 following the multiple administrations (i.e., last/sixth dose) of prototype formulations and the reference formulation. This includes the following:16 mg prototype 2 tablet (Fasted) on Day 24, 16 mg prototype 2 tablet (Fed) administered on Day 30 and 16 mg Prototype 2 tablet + PPI (Fasted) administered on Day 36.

Time frame:
Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours post-dose (Days 24, 30 and 36)
Reported as:
Median · hours
Part B: PK: Time of Maximum Observed Concentration (Tmax) of LY3502970 Following Multiple Oral Doses of Prototype Formulations Compared to the Reference Formulation
hoursPart B
16 mg prototype 2 tablet (Fasted) (Day 24)8.00 (4.00 to 12.00)
16 mg prototype 2 tablet (Fed) (Day 30)7.00 (2.00 to 16.05)
16 mg Prototype 2 tablet + PPI (Fasted) (Day 36)7.00 (4.00 to 12.00)

Adverse events

Collected over Baseline to the end of follow-up (up to Day 53). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - 2 mg Capsule0/12 (0%)0/12 (0%)11/12 (91.7%)
Part A - 4 mg Capsule0/12 (0%)0/12 (0%)11/12 (91.7%)
Part A - 8 mg Capsule0/12 (0%)0/12 (0%)11/12 (91.7%)
Part A - 16 mg Capsule0/11 (0%)0/11 (0%)11/11 (100%)
Part A - 16 mg Prototype 1 Tablet0/10 (0%)0/10 (0%)9/10 (90%)
Part A - 16 mg Prototype 2 Tablet0/10 (0%)0/10 (0%)8/10 (80%)
Part B - 2 mg Capsule0/14 (0%)0/14 (0%)13/14 (92.9%)
Part B - 4 mg Capsule0/14 (0%)0/14 (0%)12/14 (85.7%)
Part B - 8 mg Capsule0/14 (0%)0/14 (0%)13/14 (92.9%)
Part B -16 mg Prototype 2 Tablet/Fasted0/14 (0%)0/14 (0%)12/14 (85.7%)
Part B - 16 mg Prototype 2 Tablet/Fed0/12 (0%)0/12 (0%)8/12 (66.7%)
Part B - 16 mg Prototype 2 Tablet + PPI0/12 (0%)0/12 (0%)8/12 (66.7%)
Most frequent other events
Showing 10 of 69
Most frequent other events
EventPart A - 2 mg CapsulePart A - 4 mg CapsulePart A - 8 mg CapsulePart A - 16 mg CapsulePart A - 16 mg Prototype 1 TabletPart A - 16 mg Prototype 2 TabletPart B - 2 mg CapsulePart B - 4 mg CapsulePart B - 8 mg CapsulePart B -16 mg Prototype 2 Tablet/FastedPart B - 16 mg Prototype 2 Tablet/FedPart B - 16 mg Prototype 2 Tablet + PPI
NauseaGastrointestinal disorders7/126/126/128/115/106/107/143/143/144/143/121/12
Weight decreasedInvestigations0/120/128/120/110/100/100/140/143/143/141/121/12
ConstipationGastrointestinal disorders5/121/124/123/110/100/107/143/143/141/141/121/12
HeadacheNervous system disorders6/123/124/122/113/100/104/142/140/144/141/121/12
Decreased appetiteMetabolism and nutrition disorders5/122/123/120/110/100/106/142/142/140/141/120/12
Abdominal distensionGastrointestinal disorders4/121/121/121/112/101/104/141/140/140/141/121/12
VomitingGastrointestinal disorders4/120/121/122/111/101/104/140/140/142/141/120/12
FatigueGeneral disorders1/120/120/120/113/100/101/140/140/140/140/120/12
DysgeusiaNervous system disorders0/120/122/121/113/100/101/140/140/140/140/120/12
Abdominal discomfortGastrointestinal disorders0/121/122/122/110/100/100/140/143/143/141/120/12

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)Part A (LY3502970)Part B (LY3502970)Total
<=18 years000
Between 18 and 65 years121426
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Part A (LY3502970)Part B (LY3502970)Total
Female314
Male91322
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A (LY3502970)Part B (LY3502970)Total
Hispanic or Latino000
Not Hispanic or Latino121426
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A (LY3502970)Part B (LY3502970)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White111425
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • Quotient Clinical Ltd
    Nottingham, NG11 6JS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2021 to primary completion in Apr 2022, 6 months.

Results were first posted in May 2026, 4 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2021
First posted
Sep 21, 2021
StartActual
Sep 16, 2021
Primary completionActual
Apr 4, 2022
CompletionActual
Apr 4, 2022
Results first posted
May 29, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05051566
Collaborators
Quotient Sciences
Responsible party
Sponsor
First posted
Sep 21, 2021
Start date
Sep 16, 2021
Primary completion
Apr 4, 2022
Completion
Apr 4, 2022
Results posted
May 29, 2026
Last update
May 29, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion